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Abstract
Individuals with BRCA2 mutations are predisposed to breast cancers owing to genome instability.
To determine the functions of BRCA 2, the human protein was purified. It was found to bind
selectively to single-stranded DNA (ssDNA), and to ssDNA in tailed duplexes and replication fork
structures. Monomeric and dimeric forms of BRCA 2 were observed by EM. BRCA 2 directed the
binding of RA D51 recombinase to ssDNA, reduced the binding of RA D51 to duplex DNA and
stimulated RA D51-mediated DNA strand exchange. These observations provide a molecular
basis for the role of BRCA 2 in the maintenance of genome stability.
Breast cancer represents one of the most common causes of cancer-associated female
mortality in the world today. Inheritable breast and ovarian cancers can be linked with
mutations in the BRCA1, BRCA2 and PALB2 genes, all of which affect the efficiency of
double-strand break repair mediated by homologous recombination1. The BRCA2 gene
encodes a protein of 3,418 amino acids, containing (i) eight conserved BRC motifs that
interact with the RAD51 recombinase2, (ii) a binding site for the meiosis-specific
recombinase DMC1 (ref. 3) and (iii) a DNA-binding domain4. BRCA2’s interactions with
RAD51 and DMC1 are required for the localization of both proteins to nuclear foci that
mark sites of DNA breakage. Additionally, there is an unrelated RAD51-binding site at the
C terminus of BRCA2 that may provide more complex levels of control during the cell cycle
and in response to DNA damage5,6.
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Efforts to understand the functions of BRCA2 have been hampered by the difficulty in
purifying the full-length human protein. Consequently, most studies have focused on protein
fragments or on small BRCA2-like proteins found in simple organisms. For example, the
Brh2 protein from the fungus Ustilago maydis and the BRC-2 protein from the nematode
Caenorhabditis elegans each contain a single BRC motif and can exert a stimulatory effect
on DNA binding by RAD51 and/or RAD51’s ability to promote DNA-DNA interactions7,8.
Similar effects have been seen with fragments of human BRCA2 (refs. 9–12).
Here we have purified full-length human BRCA2 from HeLa cells carrying a human
bacterial artificial chromosome (BAC), in which the BRCA2 gene, complete with upstream
and downstream regulatory elements, was FLAP tagged at either the N- or C-terminus13.
The FLAP tag is composed of green fluorescent protein (GFP), S- and Flag-affinity tags
separated by PreScission- and TEV-protease sites (Supplementary Fig. 1). The N- and C-
terminally tagged BRCA2 proteins were purified by Flag- and GFP-affinity purification, and
the GFP and S tags were removed by TEV cleavage, leaving just a small, 1.3 kDa Flag tag
(Supplementary Methods). The purified proteins were soluble and SDS-PAGE revealed that
both protein preparations were of high quality (Fig. 1a). A small amount of PALB2, a high-
affinity BRCA2 interaction partner14, co-purified with the N-terminally tagged BRCA2,
whereas much less was associated with the C-terminally tagged protein. The reason for this
difference is unknown, and both preparations behaved similarly in the experiments
described here.
To determine whether BRCA2 binds to DNA, N-terminally Flag-tagged BRCA2 was
incubated with 5′-32P end-labeled ssDNA or double-stranded DNA (dsDNA). BRCA2
bound ssDNA in a concentration-dependent manner (Fig. 1b, left), whereas it did not form
stable complexes with dsDNA (Fig. 1b, right). Similar results were obtained with C-
terminally Flag-tagged BRCA2 (Supplementary Fig. 2). These results show that full-length
BRCA2 is an ssDNA-binding protein, as suggested by previous studies of a fragment of
BRCA2 containing the DNA-binding domain4.
When Flag-BRCA2 (385 kDa) was visualized by electron microscopy after rotary tungsten
shadowcasting, we observed a mixture of ball-shaped (that is, roughly spherical) particles
and elongated rod-shaped particles with the appearance of a dumbbell (Fig. 1c). The balls
had a mean diameter of 15 ± 2 nm (including tungsten coating), whereas the rods were 16 ±
2 nm wide and 27 ± 3 nm long. In some instances longer BRCA2 rods were observed. The
masses of the ball- and rod-shaped particles were determined by comparison with ferritin
(440 kDa), revealing relative masses of 337 and 860 kDa, respectively (Supplementary Fig.
3), consistent with BRCA2 monomers and dimers. These observations were confirmed with
unfixed BRCA2 protein using negative staining (data not shown).
Because tailed duplex DNA provides a good model substrate for structures that initiate
homologous recombination–mediated double-strand break (DSB) repair, we visualized the
binding of BRCA2 to a 3.5-kb linear duplex containing a 54-nt 3′-extended ssDNA tail at
one end and a blunt end at the other. Examination of 129 molecules with bound protein (out
of a total of 310 DNA molecules) showed that 91% had BRCA2 bound exclusively to one
end of the DNA substrate (Fig. 2). No example was found in which BRCA2 bound to both
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DNA termini. Only infrequently (9%) did we observe the apparent association of BRCA2
with internal duplex regions of DNA. Inspection of the end-bound BRCA2 proteins showed
that these particles had dimensions of 19 ± 4 nm wide and 34 ± 6 nm long (n = 15),
consistent with the rod-shaped BRCA2 dimers observed in the absence of DNA.
We also analyzed the interaction of BRCA2 with replication fork structures containing a 25-
nt-long region of ssDNA at the fork. Upon scoring 124 molecules, we found that 50 DNA
molecules had bound BRCA2 protein and that in 75% of these cases BRCA2 was bound to
the junction (Supplementary Fig. 4). Less frequently, BRCA2 appeared to be attached to
internal duplex DNA (16%) or at the ends of the junction arm (10%). Given the preference
of BRCA2 for binding ssDNA, these results are consistent with the interaction of BRCA2 to
the ssDNA present at the replication fork. With the fork substrate, we observed the binding
of both ball- and rod-shaped BRCA2 particles.
Whereas Escherichia coli RecA protein shows a high affinity for ssDNA compared with
duplex DNA, RAD51 protein binds both ssDNA and dsDNA15. This lack of specificity is
problematic for recombination because it is known that homologous recombination is
initiated by the binding of RAD51 to resected ssDNA tails at sites of DNA breaks, which
then interact and pair with RAD51-free duplex DNA. These observations led to suggestions
that RAD51 requires a targeting factor that mediates its interaction with ssDNA. To
determine whether BRCA2 modulates the DNA binding affinities of RAD51, we conducted
DNA binding assays under conditions of low ionic strength, in which BRCA2 binds ssDNA
(Supplementary Fig. 5), whereas RAD51 shows the same affinity for both ssDNA and
dsDNA (Supplementary Fig. 6). The reactions included both Mg2+ and ATP to facilitate the
formation of extended RAD51 nucleoprotein filaments, which are known to be the
functionally active form of the protein. We found that the presence of low amounts of
BRCA2 resulted in a significant increase in ssDNA binding by RAD51 (Fig. 3a, lanes 2–5).
Conversely, BRCA2 reduced the ability of RAD51 to bind dsDNA, thus providing the
differential targeting necessary for homologous recombination (Fig. 3a, lanes 8–11). Further
analysis of the way that BRCA2 stimulates RAD51 nucleoprotein filament formation
revealed no evidence of a ternary BRCA2–RAD51–DNA complex, suggesting that BRCA2
may act as a molecular chaperone for RAD51 loading (Fig. 3b).
Because BRCA2 targets the binding of RAD51 to ssDNA rather than dsDNA, a reaction
likely to be important for RAD51 activity, we next analyzed whether BRCA2 could
stimulate RAD51-mediated strand exchange. To do this, we first bound BRCA2 to tailed
duplex DNA and then added RAD51 protein and a 32P-labeled duplex. The presence of
BRCA2 resulted in the transfer of the 32P-labeled strand of the duplex to the tailed substrate
(Fig. 3c). These results indicate that full-length BRCA2 protein stimulates RAD51-mediated
DNA strand exchange.
The results presented here provide our first insights into the actions and structure of this
important tumor suppressor. We have shown that BRCA2 associates with ssDNA, promotes
the specific targeting of RAD51 to ssDNA tails on duplex DNA molecules resembling
structures that initiate homologous recombination in vivo and stimulates RAD51-mediated
DNA strand exchange. These reactions are likely to be important in terms of BRCA2’s
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biological functions in the maintenance of genome stability. Electron microscopic analyses
revealed two distinct particle sizes, with masses suggesting monomeric and dimeric forms of
BRCA2. Dimer formation would be consistent with the crystallographic dimer observed
during X-ray analysis of the DNA-binding domain of BRCA2 (ref. 4) and the observed
dimeric forms of U. maydis Brh2 (ref. 16). Monomeric and dimeric forms of BRCA2 were
visualized binding to regions of ssDNA present within tailed or replication fork substrates.
The association of multiple BRCA2 units (either monomeric or dimeric) with regions of
ssDNA suggests a rapid mechanism for the loading of RAD51 onto ssDNA. Given that we
do not observe a ternary complex containing BRCA2–RAD51–ssDNA, our results indicate
that BRCA2 acts as a molecular chaperone that facilitates the binding of RAD51 and then
dissociates itself from the ssDNA. RAD51 monomers associate to form heptameric ring
structures in solution17, and it is possible that the BRC repeats might collectively fold in
such a way as to favor associations with RAD51 rings. As such, the actual amount of
RAD51 bound by each BRCA2 unit could be considerably greater than the number of BRC
repeats. How BRCA2 blocks binding of RAD51 to dsDNA is at present unknown but, given
that there are eight BRC motifs per BRCA2 monomer, one scenario would be that BRCA2
binds RAD51 such that the critical concentration of free RAD51 in solution drops to the
point where dsDNA binding does not take place.
The role of BRCA2 in the targeting of RAD51 is analogous to the way that Rad52 delivers
Rad51 to ssDNA substrates for homologous recombination in yeast. In yeast, the
recruitment of Rad51 to resected DSBs is dependent upon Rad52 in both mitotic and meiotic
cells18, and in vitro studies show that Rad52 facilitates the formation of Rad51 filaments on
RPA-bound ssDNA19,20. However, a defined mediator role for RAD52 in human cells has
not been demonstrated, which may account for the lack of a clear DSB repair–defective
phenotype in Rad52−/− mice21,22. It is possible that the eight BRC motifs in BRCA2 provide
a rapid mechanism for the loading of RAD51 to ssDNA, such that the evolutionary
development of BRCA2 has relegated RAD52 to a more minor, or alternative, role in DNA
repair and genome maintenance.
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Purified BRCA2 binds specifically to ssDNA. (a) N- or C-terminally FLAG-tagged BRCA2
was purified from human cells and analyzed by SDS-PAGE and SyPro Ruby staining. M,
size marker. (b) Purified N-terminally Flag-tagged BRCA2 was incubated with 5′-32P end-
labeled ssDNA or dsDNA, and complexes were analyzed by agarose gel electrophoresis and
visualized by autoradiography. (c) Electron microscopic visualization of BRCA2. Top: large
field of N-terminally Flag-tagged BRCA2 protein, rotary shadowcast with tungsten. Scale
bar, 40 nm. Arrows, ball-shaped BRCA2 particles; arrows with asterisks, rod-shaped
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particles. Below: individual protein particles at higher magnification. Scale bar, 25 nm.
Images are shown in reverse contrast.
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Binding of BRCA2 to tailed duplex DNA. N-terminally Flag-tagged BRCA2 protein was
incubated with linear duplex DNA (3.5 kb long) containing a 54-nt ssDNA overhang at one
end. Samples were fixed, mounted on glow-discharged carbon grids and rotary shadowcast
with tungsten. Top: BRCA2 localizes to ssDNA tails of the duplex DNA substrate. Scale
bar, 100 nm. Bottom: higher magnification images of dumbbell-shaped BRCA2 dimers
bound to ssDNA tails. Scale bar, 50 nm. Images are shown in reverse contrast.
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BRCA2 targets RAD51 to ssDNA and stimulates DNA strand exchange. (a) BRCA2 and
RAD51 were mixed in binding buffer for 5 min at 24 °C, before the addition of 32P-labeled
ssDNA or dsDNA. Incubation was then continued for 10 min, before complexes were fixed
and analyzed by agarose gel electrophoresis and autoradiography. (b) BRCA2 was
incubated for 5 min at 24 °C with 32P-labeled ssDNA, before RAD51 addition. Incubation
was then continued for a further 5 min. Complexes were analyzed as in a. (c) Stimulation of
RAD51-mediated strand exchange by BRCA2. Tailed duplex DNA was incubated with
BRCA2 for 5 min before the addition of RAD51. After a further 5 min, 5′-32P end-labeled
(*) duplex DNA (35 bp) was added and incubation continued for 10 min. The products were
deproteinized and analyzed by 10% PAGE, followed by autoradiography.
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